Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.56 |
| ▸ | MERTK | Q12866 | 6/20 | 0.42 |
| ▸ | AXL | P30530 | 5/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 5/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | PTAFR | P25105 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095888 | 0.86 | ESR1 (0.58) | ESR1ESR2MERTKAXLTYRO3 | |
| SCHEMBL25206226 | 0.82 | ESR2 (0.76) | ESR1ESR2PKMGAAMEN1 | |
| SCHEMBL2821470 | 0.82 | ESR1 (0.76) | ESR1ESR2MERTKAXLTYRO3 | |
| SCHEMBL29989790 | 0.82 | ESR1 (0.76) | ESR1ESR2MERTKAXLTYRO3 | |
| SCHEMBL14282040 | 0.81 | ESR1 (0.51) | ESR1ESR2NOTUMPTAFRMEN1 | |
| SCHEMBL29677011 | 0.81 | ESR1 (0.51) | ESR1ESR2NOTUMPTAFRMEN1 | |
| SCHEMBL13012424 | 0.81 | ESR1 (0.49) | ESR1ESR2PKMGAAMEN1 | |
| SCHEMBL2585109 | 0.79 | ESR1 (0.62) | ESR1ESR2PKMNOTUMTAS1R3 | |
| SCHEMBL28724571 | 0.79 | ESR1 (0.49) | ESR1ESR2MERTKAXLTYRO3 | |
| SCHEMBL28724568 | 0.75 | ESR1 (0.45) | ESR1ESR2PKMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2374796-B1 | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorderes | ARENA PHARM INC (US) | 2018-02-28 | — | — | EP | claimed |
| US-8846906-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | claimed |
| US-20130217676-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-08-22 | — | — | US | claimed |
| EP-2374796-A1 | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorders | Arena Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | claimed |
| EP-2363394-A1 | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorders | Arena Pharmaceuticals, Inc. (US) | 2011-09-07 | — | — | EP | claimed |
| EP-2374796-B1 | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorderes | ARENA PHARM INC (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-2374796-B1 | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorderes | ARENA PHARM INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160250223-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2016-09-01 | — | — | US | disclosed |
| US-20160024014-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-8993750-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150087634-A1 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS | ARENA PHARMACEUTICALS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-20150045552-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2015-02-12 | — | — | US | disclosed |
| WO-2005042491-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005042490-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| EP-1411881-B1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2005-05-04 | — | — | EP | disclosed |
| US-20050020573-A1 | Obesity; using 3-benoazepine compound | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | US | disclosed |
| EP-1411881-A4 | 5HT sb 2C /sb RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2004-07-07 | — | — | EP | disclosed |
| EP-1411881-A2 | 5HT sb 2C /sb RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030225057-A1 | 3-Benzoazepine derivatives | ARENA PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2003086306-A2 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225057-A1 | 3-Benzoazepine derivatives | HTR2C, HTR1A, HTR3A | ESR1 1510/4885ESR2 848/4885MERTK 3969/4885 |
| US-20050020573-A1 | Obesity; using 3-benoazepine compound | HTR2C, HTR3C, HTR3B | ESR1 2872/4885ESR2 1307/4885MERTK 4516/4885 |
| US-20130217676-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | ESR1 1469/4885ESR2 559/4885MERTK 3583/4885 |
| US-20150087634-A1 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS | HTR2C, HTR2A, HTR5A | ESR1 1578/4885ESR2 1476/4885MERTK 1983/4885 |
| US-20160024014-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | ESR1 1469/4885ESR2 559/4885MERTK 3583/4885 |
| US-20150045552-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | ESR1 1469/4885ESR2 559/4885MERTK 3583/4885 |
| US-20160250223-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | ESR1 1469/4885ESR2 559/4885MERTK 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.